The Chemerin Receptor CMKLR1 Requires Full‐Length Chemerin for High Affinity in Contrast to GPR1 as Demonstrated by a New Nanoluciferase‐based Binding Assay

Anne Sophie Czerniak,Kevin Kretschmer,Tina Weiß,Annette G. Beck-Sickinger
DOI: https://doi.org/10.1002/cmdc.202200413
IF: 3.54
2022-10-06
ChemMedChem
Abstract:To study the binding mode of the adipokine chemerin as well as of the short peptide agonist chemerin‐9 (C9) to its two receptors chemokine‐like receptor 1 (CMKLR1) and G protein‐coupled receptor 1 (GPR1), we generated 5‐carboxytetra­methyl­rhodamine (TAMRA) modified variants of both ligands. In addition, we labeled GPR1 and CMKLR1 with a nanoluciferase at the N‐terminus to perform NanoBRET binding assays. For GPR1, both ligands show high affinity and comparable binding. Significant differences were found for CMKLR1, whereby only full‐length chemerin binds with high affinity in saturation and displacement assays. For TAMRA‐C9 a biphasic binding consisting of two binding states has been found and no displacement studies could be performed. Thus, we conclude that CMKLR1 requires full‐length chemerin for stable binding in contrast to GPR1. This work demonstrates that the NanoBRET binding assay is a new tool for binding studies at chemerin receptors and it enables deeper insights into the ligand binding parameters.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?